Form 4: ClearPoint Neuro Executive Awarded Restricted Stock Units
SEC Form 4 Filing
Jeremy L. Stigall, Chief Business Officer of ClearPoint Neuro, Inc., was granted 77,487 restricted stock units (RSUs) on May 20, 2024, which will vest over a three-year period.
Summary
- On May 20, 2024, Jeremy L. Stigall, the Chief Business Officer of ClearPoint Neuro, Inc., received 77,487 restricted stock units (RSUs).
- These RSUs represent a contingent right to receive one share of CLPT common stock per unit.
- The RSUs will vest in three tranches: 20% on March 12, 2025, 40% on March 12, 2026, and the remaining 40% on March 12, 2027.
Sentiment
Score: 7
Explanation: The document indicates a standard executive compensation practice, suggesting stability and alignment of interests. The sentiment is moderately positive as it reflects ongoing investment in key personnel.
Positives
- The grant of RSUs to a key executive like the Chief Business Officer suggests an incentive alignment with the company's long-term performance.
- The vesting schedule encourages continued service and contribution from the executive over the next three years.
Future Outlook
The vesting schedule indicates a commitment to long-term value creation and retention of key personnel.
Industry Context
Granting stock-based compensation is a common practice in the biotech and medical device industries to attract, retain, and incentivize key executives. The vesting schedule is typical for such grants.
Comparison to Industry Standards
- Stock-based compensation is a standard practice in the medical device industry.
- Companies like Medtronic and Stryker also use stock options and RSUs to incentivize their executives.
- The vesting schedule of ClearPoint Neuro's RSUs is comparable to industry norms, typically spanning three to five years.
Stakeholder Impact
- Shareholders may view the RSU grant as a positive sign, indicating the company's commitment to retaining key talent.
- Employees may see this as a positive signal about the company's financial health and future prospects.
Key Dates
| Date | Description |
|---|---|
| 05/20/2024 | Date of transaction: Grant of restricted stock units. |
| 03/12/2025 | 20% of the restricted stock units vest. |
| 03/12/2026 | 40% of the restricted stock units vest. |
| 03/12/2027 | 40% of the restricted stock units vest. |
| 05/22/2024 | Date of filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.